Farnesyltransferase Inhibitors in Cancer Therapy:
With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Totowa, NJ
Humana Press
2001
|
| Series: | Cancer Drug Discovery and Development
|
| Subjects: | |
| Online Access: | UBR01 Volltext |
| Summary: | With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer-causing activity. In Farnesyltransferase Inhibitors in Cancer Therapy, cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase inhibitors (GGTIs) that can be used as anticancer drugs and in cardiovascular and parasitic therapy. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. The book also discusses the results from several phase I and II human clinical trials using a variety of FTIs, and demonstrates the design of hypothesis-driven clinical trials with proof-of-concept using biochemical endpoints. Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors |
| Physical Description: | 1 Online-Ressource (XII, 280 p) |
| ISBN: | 9781592590131 |
| DOI: | 10.1007/978-1-59259-013-1 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046144821 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2001 |||| o||u| ||||||eng d | ||
| 020 | |a 9781592590131 |9 978-1-59259-013-1 | ||
| 024 | 7 | |a 10.1007/978-1-59259-013-1 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-59259-013-1 | ||
| 035 | |a (OCoLC)1119119565 | ||
| 035 | |a (DE-599)BVBBV046144821 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 245 | 1 | 0 | |a Farnesyltransferase Inhibitors in Cancer Therapy |c edited by Saïd M. Sebti, Andrew D. Hamilton |
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 2001 | |
| 300 | |a 1 Online-Ressource (XII, 280 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer Drug Discovery and Development | |
| 520 | |a With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer-causing activity. In Farnesyltransferase Inhibitors in Cancer Therapy, cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase inhibitors (GGTIs) that can be used as anticancer drugs and in cardiovascular and parasitic therapy. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. The book also discusses the results from several phase I and II human clinical trials using a variety of FTIs, and demonstrates the design of hypothesis-driven clinical trials with proof-of-concept using biochemical endpoints. Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Pharmaceutical Sciences/Technology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Pharmaceutical technology | |
| 700 | 1 | |a Sebti, Saïd M. |4 edt | |
| 700 | 1 | |a Hamilton, Andrew D. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781468496062 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780896036291 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781468496055 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-59259-013-1 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525006 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-59259-013-1 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Record in the Search Index
| _version_ | 1804180480713555968 |
|---|---|
| any_adam_object | |
| author2 | Sebti, Saïd M. Hamilton, Andrew D. |
| author2_role | edt edt |
| author2_variant | s m s sm sms a d h ad adh |
| author_facet | Sebti, Saïd M. Hamilton, Andrew D. |
| building | Verbundindex |
| bvnumber | BV046144821 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-59259-013-1 (OCoLC)1119119565 (DE-599)BVBBV046144821 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-59259-013-1 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03095nmm a2200457zc 4500</leader><controlfield tag="001">BV046144821</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2001 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781592590131</subfield><subfield code="9">978-1-59259-013-1</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-59259-013-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-59259-013-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119119565</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046144821</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Farnesyltransferase Inhibitors in Cancer Therapy</subfield><subfield code="c">edited by Saïd M. Sebti, Andrew D. Hamilton</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XII, 280 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer Drug Discovery and Development</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer-causing activity. In Farnesyltransferase Inhibitors in Cancer Therapy, cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase inhibitors (GGTIs) that can be used as anticancer drugs and in cardiovascular and parasitic therapy. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. The book also discusses the results from several phase I and II human clinical trials using a variety of FTIs, and demonstrates the design of hypothesis-driven clinical trials with proof-of-concept using biochemical endpoints. Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical Sciences/Technology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical technology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sebti, Saïd M.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamilton, Andrew D.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781468496062</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780896036291</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781468496055</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-59259-013-1</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525006</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-59259-013-1</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046144821 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:26Z |
| institution | BVB |
| isbn | 9781592590131 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525006 |
| oclc_num | 1119119565 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XII, 280 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | Humana Press |
| record_format | marc |
| series2 | Cancer Drug Discovery and Development |
| spelling | Farnesyltransferase Inhibitors in Cancer Therapy edited by Saïd M. Sebti, Andrew D. Hamilton Totowa, NJ Humana Press 2001 1 Online-Ressource (XII, 280 p) txt rdacontent c rdamedia cr rdacarrier Cancer Drug Discovery and Development With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer-causing activity. In Farnesyltransferase Inhibitors in Cancer Therapy, cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase inhibitors (GGTIs) that can be used as anticancer drugs and in cardiovascular and parasitic therapy. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. The book also discusses the results from several phase I and II human clinical trials using a variety of FTIs, and demonstrates the design of hypothesis-driven clinical trials with proof-of-concept using biochemical endpoints. Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors Oncology Pharmaceutical Sciences/Technology Oncology Pharmaceutical technology Sebti, Saïd M. edt Hamilton, Andrew D. edt Erscheint auch als Druck-Ausgabe 9781468496062 Erscheint auch als Druck-Ausgabe 9780896036291 Erscheint auch als Druck-Ausgabe 9781468496055 https://doi.org/10.1007/978-1-59259-013-1 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Farnesyltransferase Inhibitors in Cancer Therapy Oncology Pharmaceutical Sciences/Technology Oncology Pharmaceutical technology |
| title | Farnesyltransferase Inhibitors in Cancer Therapy |
| title_auth | Farnesyltransferase Inhibitors in Cancer Therapy |
| title_exact_search | Farnesyltransferase Inhibitors in Cancer Therapy |
| title_full | Farnesyltransferase Inhibitors in Cancer Therapy edited by Saïd M. Sebti, Andrew D. Hamilton |
| title_fullStr | Farnesyltransferase Inhibitors in Cancer Therapy edited by Saïd M. Sebti, Andrew D. Hamilton |
| title_full_unstemmed | Farnesyltransferase Inhibitors in Cancer Therapy edited by Saïd M. Sebti, Andrew D. Hamilton |
| title_short | Farnesyltransferase Inhibitors in Cancer Therapy |
| title_sort | farnesyltransferase inhibitors in cancer therapy |
| topic | Oncology Pharmaceutical Sciences/Technology Oncology Pharmaceutical technology |
| topic_facet | Oncology Pharmaceutical Sciences/Technology Oncology Pharmaceutical technology |
| url | https://doi.org/10.1007/978-1-59259-013-1 |
| work_keys_str_mv | AT sebtisaidm farnesyltransferaseinhibitorsincancertherapy AT hamiltonandrewd farnesyltransferaseinhibitorsincancertherapy |